Tumor fitness, immune exhaustion and clinical outcomes: impact of immune checkpoint inhibitors
A. Bubie, E. G. Kozlova, N. Akers, A. Villanueva, B. Losic
The paper evaluates tumor fitness measures based on neoepitope profiling for predicting immune checkpoint inhibitor response and finds no significant survival benefit beyond tumor mutation burden.
bioRxiv · Jan 13, 2020Cancer Biology